BRCA1 Inhibits Membrane Estrogen and Growth Factor Receptor Signaling to Cell Proliferation in Breast Cancer

REFERENCES

• Baer, R., and Ludwig T.. 2002. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 12:86–91.
   PubMed Web of Science ®Google Scholar
• Casey, G. 1995. The BRCA1 and BRCA2 breast cancer genes. Curr. Opin. Oncol. 9:88–93.
   Google Scholar
• Chen, Y., Farmer A. A., Chen C.-F., Jones D. C., Chen P.-L., and Lee W.-H.. 1996. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 56:3168–3172.
   PubMed Web of Science ®Google Scholar
• Chu, Y., Solski P. A., Khosravi-Far R., Der C. J., and Kelly K.. 1996. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J. Biol. Chem. 271:6497–6501.
   PubMed Web of Science ®Google Scholar
• Couse, J. F., Curtis S. W., Washburn T. F., Lindzey J., Golding T. S., Lubahn D. B., Smithies O., and Korach K. S.. 1995. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol. Endocrinol. 9:1441–1454.
   PubMed Web of Science ®Google Scholar
• Fan, S., Wang J.-A., Yuan R., Ma Y., Meng Q., Erdos M. R., Pestell R. G., Yuan F., Auborn K. J., Goldberg I. D., and Rosen E. M.. 1999. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284:1354–1356.
   PubMed Web of Science ®Google Scholar
• Fan, S., Ma Y. X., Wang C., Yuan R. Q., Meng Q., Wang J. A., Erdos M., Goldberg I. D., Webb P., Kushner P. J., Pestell R. G., and Rosen E. M.. 2001. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20:77–87.
   PubMed Web of Science ®Google Scholar
• Filardo, E. J., Quinn J. A., Bland K. I., and Frackelton A. R.. 2000. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, gpr30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14:1649–1660.
   PubMed Web of Science ®Google Scholar
• Fruman, D. A., Meyers R. E., and Cantley L. C.. 1998. Phosphoinositide kinases. Annu. Rev. Biochem. 67:481–507.
   PubMed Web of Science ®Google Scholar
• Gowen, L. C., Avrutskaya A. V., Latour A. M., Koller B. H., and Leadon S. A.. 1998. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281:1009–1012.
   PubMed Web of Science ®Google Scholar
• Harkin, D. P., Bean J. M., Miklos D., Song Y.-H., Truong V. B., Englert C., Christians F. C., Ellisen L. W., Maheswaran S., Oliner J. D., and Haber D. A.. 1999. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97:575–586.
   PubMed Web of Science ®Google Scholar
• Kaufmann, K., and Thiel G.. 2002. Epidermal growth factor and thrombin induced proliferation of immortalized human keratinocytes is coupled to the synthesis of Egr-1, a zinc finger transcriptional regulator. J. Cell. Biochem. 85:381–391.
   PubMed Web of Science ®Google Scholar
• Kousteni, S., Bellido T., Plotkin L. I., O'Brien C. A., Bodenner D. L., Han L., Han K., DiGregorio G. B., Katzenellenbogen J. A., Katzenellenbogen B. S., Roberson P. K., Weinstein R. S., Jilka R. L., and Manolagas S. C.. 2001. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719–730.
   PubMed Web of Science ®Google Scholar
• Kumar, R., Wang E.-A., Mazumdar A., Talukder A. H., Mandal M., Yang Z., Bagheri-Yarmand R., Sahin A., Hortobagyi G., Adam L., Barnes C. J., and Vadlamudi R. K.. 2002. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418:654–657.
   PubMedGoogle Scholar
• Levin, E. R. 2003. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 17:309–317.
   PubMedGoogle Scholar
• Loman, N., Johannsson O., Bendahl P. O., Borg A., Ferno M., and Olsson H.. 1998. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83:310–319.
   PubMed Web of Science ®Google Scholar
• MacLachlan, T. K., Takimoto R., and El-Deiry W. S.. 2002. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol. 22:4280–4292.
   PubMed Web of Science ®Google Scholar
• Marino, M., Acconcia F., Bresciani F., Weisz A., and Trentalance A.. 2002. Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells. Mol. Biol. Cell. 13:3720–3729.
   PubMed Web of Science ®Google Scholar
• Marks, J. R., Huper G., Vaughn J. P., Davis P. L., Norris J., McDonnell D. P., Wiseman R. W., Futreal P. A., and Iglehart J. D.. 1997. BRCA1 expression is not directly responsive to estrogen. Oncogene 14:115–121.
   PubMed Web of Science ®Google Scholar
• Marquez, D. C., and Pietras R. J.. 2001. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20:5420–5430.
   PubMed Web of Science ®Google Scholar
• Miki, Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W., et al. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–72.
   PubMed Web of Science ®Google Scholar
• Moynahan, M. E., Chiu J. W., Koller B. H., and Jasin M.. 1999. Brca1 controls homology-directed DNA repair. Mol. Cell 4:511–518.
   PubMed Web of Science ®Google Scholar
• Murphy, L. O., Smith S., Chen R. H., Fingar D. C., and Blenis J.. 2002. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell. Biol. 4:556–564.
   PubMed Web of Science ®Google Scholar
• Pedram, A., Razandi M., Aitkenhead M., Hughes C. C. W., and Levin E. R.. 2002. Integration of the non-genomic and genomic actions of estrogen: membrane initiated signaling by steroid (MISS) to transcription and cell biology. J. Biol. Chem. 277:50768–50775.
   PubMed Web of Science ®Google Scholar
• Pedram, A., Razandi M., and Levin E. R.. 2002. Deciphering VEGF signaling to vascular permeability: inhibition by atrial natriuretic peptide. J. Biol. Chem. 277:44385–44398.
   PubMedGoogle Scholar
• Pedram, A., Razandi M., Hu R.-M., and Levin E. R.. 1998. Astrocyte progression through G1-S phase of the cell cycle depends upon multiple protein interactions. J. Biol. Chem. 273:13966–13972.
   PubMedGoogle Scholar
• Pines, J., and Hunter T.. 1992. Cyclins A and B1 in the human cell cycle. Ciba Found. Symp. 170:187–196.
   PubMedGoogle Scholar
• Prenzel, N., Zwick E., Leserer M., and Ullrich A.. 2000. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2:184–190.
   PubMedGoogle Scholar
• Razandi, M., Pedram A., and Levin E. R.. 2000. Estrogen signals to preservation of endothelial cell form and function. J. Biol. Chem. 275:38540–38546.
   PubMed Web of Science ®Google Scholar
• Razandi, M., Alton G., Pedram A., Ghonshani S., Webb P., and Levin E. R.. 2003. Identification of a structural determinant necessary for the localization and function of estrogen receptor α at the plasma membrane. Mol. Cell. Biol. 23:1633–1646.
   PubMed Web of Science ®Google Scholar
• Razandi, M., Oh P., Pedram A., Schnitzer J., and Levin E. R.. 2002. Estrogen receptors associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol. Endocrinol. 16:100–115.
   PubMedGoogle Scholar
• Razandi, M., Pedram A., Parks S., and Levin E. R.. 2003. Proximal events in ER signaling from the plasma membrane. J. Biol. Chem. 278:2701–2712.
   PubMed Web of Science ®Google Scholar
• Rebbeck, T. R., Levin A. M., Eisen A., Snyder C., Watson P., Cannon-Albright L., Isaacs C., Olopade O., Garber J. E., Godwin A. K., Dal M. B., Narod S. A., Neuhausen S. L., Lynch H. T., and Weber B. L.. 1999. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst. 91:1475–1479.
   PubMed Web of Science ®Google Scholar
• Robbins, D. J., Zhen E., Owaki H., Vanderbilt C. A., Ebert D., Geppert T. D., and Cobb M. H.. 1993. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J. Biol. Chem. 268:5097–5106.
   PubMed Web of Science ®Google Scholar
• Santen, R. J., and Petroni G. R.. 1999. Relative versus attributable risk of breast cancer from estrogen replacement. J. Clin. Endocrinol. Metabol. 84:1875–1881.
   PubMed Web of Science ®Google Scholar
• Santen, R. J., Song R. X., McPherson R., Kumar R., Adam L., Jeng M. H., and Yue W.. 2002. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 80:239–256.
   PubMed Web of Science ®Google Scholar
• Scully, R., and Livingston D. M.. 2000. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408:429–432.
   PubMed Web of Science ®Google Scholar
• Shao, N., Chai Y. L., Shyam E., Reddy P., and Rao V. N.. 1996. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 13:1–7.
   PubMed Web of Science ®Google Scholar
• Singer, C. A., Figueroa-Masot X. A., Batchelor R. H., and Dorsa D. M.. 1999. The mitogen activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J. Neurosci. 19:2455–2463.
   PubMed Web of Science ®Google Scholar
• Somasundaram, K., Zhang H., Zeng Y.-X., Houvras Y., Peng Y., Zhang H., Wu G. S., Licht J. D., Weber B. L., and El-Deiry W. S.. 1997. Arrest of the cell cycle by the tumor-suppressor BRCA1 requires the CDK-inhibitor p21waf1/CiP1. Nature 280:187–189.
   Google Scholar
• Stoica, G. E., Franke T. F., Wellstein A., Czubayko F., List H. J., Reiter R., Morgan E., Martin M. B., and Stoica A.. 2003. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol. Endocrinol. 17:818–830.
   PubMed Web of Science ®Google Scholar
• Stratton, M. R., Ford D., Neuhasen S., Seal S., Wooster R., Friedman L. S., King M. C., Egilsson V., Devilee P., McManus R., et al. 1994. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat. Genet. 7:103–107.
   PubMed Web of Science ®Google Scholar
• Stuart, N. S., Warwick J., Blackledge G. R., Spooner D., Keen C., Taylor A. R., Tyrell C., Webster D. J., and Earl H.. 1996. A randomized phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur. J. Cancer 32:1888–1892.
   Google Scholar
• Svegliati-Baroni, G., Ridolfi F., Di Sario A., Casini A., Marucci L., Gaggiotti G., Orlandoni P., Macarri G., Perego L., Benedetti A., and Folli F.. 1999. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 29:1743–1751.
   PubMed Web of Science ®Google Scholar
• Tomlinson, G. E., Chen T. T.-L., Stastny V. A., Kirmani A. K., Spillman M. A., Tonk V., Blum J. L., Schneider N. R., Wistuba I. I., Shay J. W., Minna J. D., and Gazdar A. F.. 1998. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 58:3237–3242.
   PubMedGoogle Scholar
• Venkitaraman, A. R. 2002. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171–182.
   PubMed Web of Science ®Google Scholar
• Watters, J. J., Chun T. Y., Kim Y. N., Bertics P. J., and Gorski J.. 2000. Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol. Endocrinol. 14:1872–1881.
   PubMedGoogle Scholar
• White, R., and Parker M. G.. 1998. Molecular mechanisms of steroid hormone action. Endocr.-Rel. Cancer 5:1–14.
   Web of Science ®Google Scholar
• Xu, X., Weaver Z., Linke S. P., Li C., Gotay J., Wang X.-W., Harris C. C., Ried T., and Deng C.-X.. 1999. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3:389–395.
   PubMed Web of Science ®Google Scholar
• Yan, Y., Haas J. P., Kim M., Sgagias M. K., and Cowan K. H.. 2002. BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. J. Biol. Chem. 277:33422–33430.
   PubMedGoogle Scholar
• Yu, Q., Geng Y., and Sicinski P.. 2001. Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017–1021.
   PubMed Web of Science ®Google Scholar
• Zhang, X., and Yee D.. 2000. Tyrosine kinase signaling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2:170–175.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Maier B., Santen R. J., and Song R. X.. 2002. Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. Biochem. Biophys. Res. Commun. 294:926–933.
   PubMed Web of Science ®Google Scholar
• Zheng, L., Annab L. A., Afshari C. A., Lee W.-H., and Boyer T. G.. 2001. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl. Acad. Sci. USA 98:9587–9592.
   PubMed Web of Science ®Google Scholar